Detail akcie Transgene SA online

Business Summary: Transgene SA is a biopharmaceutical company. The Company designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The Company has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B. The Company also has various other programs based on its viral vector technology in research or in pre-clinical or clinical development. The Company's activities are focused on human health and, in particular, the research and development of immunotherapy products, including therapeutic vaccines and oncolytic viruses in the field of cancer and infectious diseases. The Company's principal products include TG4010 (MVA-MUC1-IL2), Pexa-Vec (VV-TK-GM-CSF), TG6002 (VV-TK-RR-FCU1), TG1050 (Ad5-HBV) and TG4001 (MVA-HPV-IL2).
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Transgene SA revenues decreased 24% to EUR7.6M. Net loss decreased 32% to EUR22.3M. Revenues reflect Revenue from research and development collaboration segment decrease of 62% to EUR1.2M, Research & Development Tax Credit segment decrease of 6% to EUR6.5M. Lower net loss reflects Other financial income/(expenses) increase from EUR2.5M (expense) to EUR7.5M (income).